Cancer immunosurveillance by CD8 T cells.

José C Crispin, George C Tsokos

Journal: F1000Research 2020;9():F1000 Faculty Rev-80

PMID: 32089832

Free Full Text on PubMed Central View on PubMed

Abstract

Clinical success attained in patients with cancer treated with checkpoint inhibitors has renewed the interest in the immune system and in particular in T cells as a therapeutic tool to eliminate tumors. Here, we discuss recent studies that evaluate the anti-tumor role of CD8 T cells and the mechanisms that interfere with this function. In particular, we review recent literature that has reported on the phenotype and transcriptome of tumor-infiltrating CD8 T cells and deciphered the mechanisms associated with failed tumor rejection.

Address: Escuela de Medicina y Ciencias de la Salud, Tecnológico de Monterrey, Mexico City, Mexico.; Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.; Department of Medicine, Beth Israel Deaconess Medical Center, Boston, USA.; Harvard Medical School, Boston, USA.

DOI: 10.12688/f1000research.21150.1

Link outs

Free resources

Full Text Sources:

Medical:

https://medlineplus.gov/cancer.html

Research Materials:

https://antibodies.cancer.gov/detail/CPTC-CD8A-1

MeSH Terms: CD8-Positive T-Lymphocytes, Humans, Lymphocytes, Tumor-Infiltrating, Monitoring, Immunologic, Neoplasms, Programmed Cell Death 1 Receptor